1
|
Tomasini P, Greillier L and Barlesi F:
Advanced non-squamous non-small-cell lung cancer: Who and when
should be biologically screened today? Tomorrow? Curr Respir Care
Rep. 2:17–21. 2013.
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016.
|
3
|
Castells M, Thibault B, Delord JP and
Couderc B: Implication of tumor microenvironment in
chemoresistance: Tumor-associated stromal cells protect tumor cells
from cell death. Int J Mol Sci. 13:9545–9571. 2012.
|
4
|
Keedy VL, Temin S, Somerfield MR, Beasley
MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and
Giaccone G: American Society of Clinical Oncology provisional
clinical opinion: Epidermal growth factor receptor (EGFR) Mutation
testing for patients with advanced non-small-cell lung cancer
considering first-line EGFR tyrosine kinase inhibitor therapy. J
Clin Oncol. 29:2121–2127. 2011.
|
5
|
Neel DS and Bivona TG: Resistance is
futile: Overcoming resistance to targeted therapies in lung
adenocarcinoma. NPJ Precis Oncol. 1:1–6. 2017.
|
6
|
Shimizu K, Nagamachi Y, Tani M, Kimura K,
Shiroishi T, Wakana S and Yokota J: Molecular cloning of a novel
NF2/ERM/4.1 superfamily gene, ehm2, that is expressed in
high-metastatic K1735 murine melanoma cells. Genomics. 65:113–120.
2000.
|
7
|
Badouel C, Gardano L, Amin N, Garg A,
Rosenfeld R, Le Bihan T and McNeill H: The FERM-domain protein
Expanded regulates Hippo pathway activity via direct interactions
with the transcriptional activator Yorkie. Dev Cell. 16:411–420.
2009.
|
8
|
Pearson MA, Reczek D, Bretscher A and
Karplus PA: Structure of the ERM protein moesin reveals the FERM
domain fold masked by an extended actin binding tail domain. Cell.
101:259–270. 2000.
|
9
|
Marešová L, Vydarený T and Sychrová H:
Comparison of the influence of small GTPases Arl1 and Ypt6 on yeast
cells’ tolerance to various stress factors. FEMS Yeast Res.
12:332–340. 2012.
|
10
|
Nakajima H and Tanoue T: Lulu2 regulates
the circumferential actomyosin tensile system in epithelial cells
through p114RhoGEF. J Cell Biol. 195:245–261. 2011.
|
11
|
Chauhan S, Pandey R, Way JF, Sroka TC,
Demetriou MC, Kunz S, Cress AE, Mount DW and Miesfeld RL: Androgen
regulation of the human FERM domain encoding gene EHM2 in a cell
model of steroid-induced differentiation. Biochem Biophys Res
Commun. 310:421–432. 2003.
|
12
|
Hashimoto Y, Shindo-Okada N, Tani M,
Takeuchi K, Toma H and Yokota J: Identification of genes
differentially expressed in association with metastatic potential
of K-1735 murine melanoma by messenger RNA differential display.
Cancer Res. 56:5266–5271. 1996.
|
13
|
Wang J, Cai Y, Penland R, Chauhan S,
Miesfeld RL and Ittmann M: Increased expression of the
metastasis-associated gene Ehm2 in prostate cancer. Prostate.
66:1641–1652. 2006.
|
14
|
Yu H, Ye L, Mansel RE, Zhang Y and Jiang
WG: Clinical implications of the influence of Ehm2 on the
aggressiveness of breast cancer cells through regulation of matrix
metalloproteinase-9 expression. Mol Cancer Res. 8:1501–1512.
2010.
|
15
|
Stegle O, Drewe P, Bohnert R, Borgwardt K
and Rätsch G: Statistical Tests for Detecting Differential
RNA-Transcript Expression from Read Counts. Nat Preced.
10:4437–4448. 2010.
|
16
|
Lixia M, Zhijian C, Chao S, Chaojiang G
and Congyi Z: Alternative splicing of breast cancer associated gene
BRCA1 from breast cancer cell line. J Biochem Mol Biol. 40:15–21.
2007.
|
17
|
Black DL: Mechanisms of alternative
pre-messenger RNA splicing. Annu Rev Biochem. 72:291–336. 2003.
|
18
|
Ghigna C, Giordano S, Shen H, Benvenuto F,
Castiglioni F, Comoglio PM, Green MR, Riva S and Biamonti G: Cell
motility is controlled by SF2/ASF through alternative splicing of
the Ron protooncogene. Mol Cell. 20:881–890. 2005.
|
19
|
Moolenaar CE, Pieneman C, Walsh FS, Mooi
WJ and Michalides RJ: Alternative splicing of neural-cell-adhesion
molecule mRNA in human small-cell lung-cancer cell line H69. Int J
Cancer. 51:238–243. 1992.
|
20
|
Sato H, Hiyama K, Ishioka S, Maeda H and
Yamakido M: Alternative splicing, but not allelic loss, of the
FHIT gene increases with development of lung cancer. Int J
Oncol. 15:81–88. 1999.
|
21
|
Venables JP: Unbalanced alternative
splicing and its significance in cancer. BioEssays. 28:378–386.
2006.
|
22
|
Yu H, Ge Z, Si Y, Chen G, Zhang Y and
Jiang WG: The splice variant Ehm2/1 in breast cancer MCF-7 cells
interacted with β-catenin and increased its localization to plasma
membrane. RSC Advances. 6:78436–78444. 2016.
|
23
|
Yuan JS, Reed A, Feng C and Stewart CN:
Statistical analysis of real-time PCR data. BMC Bioinformatics.
7:852006.
|
24
|
Gary R and Bretscher A: Ezrin
self-association involves binding of an N-terminal domain to a
normally masked C-terminal domain that includes the F-actin binding
site. Mol Biol Cell. 6:1061–1075. 1995.
|
25
|
Loie E, Charrier LE, Sollier K, Masson JY
and Laprise P: CRB3A Controls the Morphology and Cohesion of Cancer
Cells through Ehm2/p114RhoGEF-Dependent Signaling. Mol Cell Biol.
35:3423–3435. 2015.
|
26
|
Chae S, Jun HO, Lee EG, Yang SJ, Lee DC,
Jung JK, Park KC, Yeom YI and Kim KW: Osteopontin splice variants
differentially modulate the migratory activity of hepatocellular
carcinoma cell lines. Int J Oncol. 35:1409–1416. 2009.
|
27
|
Mori T, Kitano K, Terawaki S, Maesaki R
and Hakoshima T: Crystallographic characterization of the radixin
FERM domain bound to the cytoplasmic tail of adhesion molecule
CD44. Acta Crystallogr Sect F Struct Biol Cryst Commun. 63:844–847.
2007.
|
28
|
Laprise P, Beronja S, Silva-Gagliardi NF,
Pellikka M, Jensen AM, McGlade CJ and Tepass U: The FERM protein
Yurt is a negative regulatory component of the Crumbs complex that
controls epithelial polarity and apical membrane size. Dev Cell.
11:363–374. 2006.
|
29
|
Gosens I, Sessa A, den Hollander AI,
Letteboer SJ, Belloni V, Arends ML, Le Bivic A, Cremers FP,
Broccoli V and Roepman R: FERM protein EPB41L5 is a novel member of
the mammalian CRB-MPP5 polarity complex. Exp Cell Res.
313:3959–3970. 2007.
|
30
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014.
|
31
|
Puisieux A, Brabletz T and Caramel J:
Oncogenic roles of EMT-inducing transcription factors. Nat Cell
Biol. 16:488–494. 2014.
|
32
|
Cervantes-Arias A, Pang LY and Argyle DJ:
Epithelial-mesenchymal transition as a fundamental mechanism
underlying the cancer phenotype. Vet Comp Oncol. 11:169–184.
2013.
|
33
|
Jezierska A and Motyl T: Matrix
metalloproteinase-2 involvement in breast cancer progression: A
mini-review. Med Sci Monit. 15:RA32–RA40. 2009.
|
34
|
Niemiec JA, Adamczyk A, Małecki K,
Majchrzyk K and Ryś J: Relationships between immunophenotype, Ki-67
index, microvascular density, Ep-CAM/P-cadherin, and MMP-2
expression in early-stage invasive ductal breast cancer. Appl
Immunohistochem Mol Morphol. 20:550–560. 2012.
|
35
|
Liu Y, Sun X, Feng J, Deng LL, Liu Y, Li
B, Zhu M, Lu C and Zhou L: MT2-MMP induces proteolysis and leads to
EMT in carcinomas. Oncotarget. 7:48193–48205. 2016.
|
36
|
John A and Tuszynski G: The role of matrix
metalloproteinases in tumor angiogenesis and tumor metastasis.
Pathol Oncol Res. 7:14–23. 2001.
|